Comparative Study for Evaluation of Efficacy, Safety and Tolerability with add on Therapy of Teneligliptin Versus other DPP4 Inhibitors in Type II Diabetes Mellitus

Background: Medical care of diabetes involves oral hypoglycemic medications and/or insulin and DPP4 inhibitors. However, the clinical data regarding the safety and effectiveness of DPP4 among Type II DM patients are still lacking. Objectives: To compare efficacy, safety and tolerability with add-on therapy of Teneligliptin versus other DPP4 inhibitors in Type II diabetes mellitus patients. Material and Methods: A single-centre, cross-sectional analytical comparative observational study was conducted in a tertiary care hospital. Total 140 individuals were selected with the purposive sampling technique and were split into two groups. Group-1 included patients with T2DM who were using Metformin-Glimepiride-Teneligliptin combination, while group-2 consisted of T2DM patients who were using Metformin-Glimepiride-Sitagliptin/ Vildagliptin combination. HbA1c measurement, FBS and adverse drug reactions were compared in both the groups. Data were represented as "frequency, percentage distribution, mean +/- standard deviation, and median (range)" where appropriate when describing variables. Results: Level of HbA1c had improved among 62(88.6%) patients taking teneligliptin as an add-on therapy which was significantly higher than the patients taking others DPP4 inhibitors 49(70%).A total of 68(97.1%) patients in group-1 while 58(82.9%) in group-2 had a level of FBS<126mg/dl. Patients using teneligliptin as an add-on therapy reported fewer adverse reactions 58(82.9%), which was less than those patients who were using other DPP4 inhibitors 63(90%). Conclusion: Teneligliptin when combined with metformin and glimepiride reduces HbA1c and FBS level more efficiently with minor side effects as compared to other DPP4 inhibitors thus improving the glycemic indices in T2DM patients.